Online inquiry

IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3079MR)

This product GTTS-WQ3079MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3079MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10788MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ1932MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ6687MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7211MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ3554MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ4093MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ14767MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ15435MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TSR-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW